Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 54 43 15 71
Acute Esophagitis 12 71


External Ids:

Disease Ontology 12 DOID:11963
ICD9CM 34 530.1
MeSH 43 D004941
NCIt 49 C9224
SNOMED-CT 67 16761005
ICD10 32 K20
UMLS 71 C0014868 C0149882

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to esophageal basaloid squamous cell carcinoma and achalasia, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Famotidine and Trimebutine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 74 Esophagitis, also spelled oesophagitis, is a disease characterized by inflammation of the esophagus. The... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2069)
# Related Disease Score Top Affiliating Genes
1 esophageal basaloid squamous cell carcinoma 34.3 TP53 EGFR
2 achalasia 33.9 TP53 TNF GAST
3 esophageal cancer 33.8 TP53 TNF PTGS2 IL6 IL4 IL1B
4 barrett esophagus 33.5 TP53 SOD2 PTGS2 IL6 GAST EGFR
5 adenocarcinoma 33.4 TP53 PTGS2 EGFR CTHRC1 ASCC1
6 peptic esophagitis 33.0 TNF PTGS2 IL6 IL1B HRH2 GAST
7 esophagus adenocarcinoma 33.0 TP53 PTGS2 EGFR
8 esophagitis, eosinophilic, 1 32.8 TSLP IL5 IL4 IL33 IL13 CCL26
9 fatty liver disease 32.5 TNF IL6 IL1B CXCL8
10 varicose veins 32.1 TNF IL6 CXCL8
11 hernia, hiatus 31.7 HRH2 GAST CYP2C19
12 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.4 PTGS2 HRH2 GAST
13 neutropenia 31.4 TP53 TNF IL6 IL1B CXCL8
14 systemic scleroderma 31.3 TNF IL6 IL4 IL1B IL13 HRH2
15 acquired immunodeficiency syndrome 31.2 TP53 TNF IL6 IL1B
16 papilloma 31.2 TP53 PTGS2 IL4 EGFR
17 small cell carcinoma 31.1 TP53 GAST EGFR
18 helicobacter pylori infection 31.1 IL1B GAST EGFR CYP2C19 CXCL8
19 cytokine deficiency 31.1 IL5 IL13
20 oral cancer 31.0 TP53 PTGS2 EGFR
21 eosinophilic gastroenteritis 31.0 TSLP IL5 IL4 IL33 CCL26 CCL11
22 candidiasis 31.0 TNF IL6 IL4 IL1B CXCL8
23 pericarditis 31.0 TNF IL6 IL1B CXCL8
24 lung abscess 30.9 TNF IL6 IL1B
25 pain agnosia 30.9 PTGS2 IL6 IL1B
26 crohn's colitis 30.9 TNF IL1B CXCL8
27 ige responsiveness, atopic 30.9 IL5 IL4 IL13
28 ileus 30.8 TNF IL6 IL1B
29 irritable bowel syndrome 30.8 TNF IL6 IL1B CXCL8
30 graft-versus-host disease 30.8 TNF IL6 IL1B
31 active peptic ulcer disease 30.8 PTGS2 HRH2 CYP2C19
32 sleep apnea 30.8 TNF IL6 IL1B CXCL8
33 exanthem 30.7 TNF IL6 IL1B EGFR CXCL8
34 alcoholic liver cirrhosis 30.7 TNF SOD2 IL6 IL1B CXCL8
35 pharyngitis 30.7 TNF PTGS2 IL6 IL1B CXCL8
36 lymphangioma 30.7 TP53 PTGS2 IL6 EGFR
37 laryngitis 30.6 TNF IL6 IL1B HRH2
38 gastrointestinal carcinoma 30.6 TP53 IL6 GAST
39 myositis 30.6 TNF IL6 IL1B CXCL8
40 cholangitis 30.6 TP53 TNF IL6 CXCL8
41 crohn's disease 30.6 TNF IL6 IL4 IL1B CXCL8
42 bacterial infectious disease 30.6 TNF IL6 IL1B CXCL8
43 lichen planus 30.6 TP53 TNF IL6 IL4 CXCL8
44 spinal cord injury 30.6 TNF IL6 CXCL8
45 lymphadenitis 30.6 TNF IL1B CXCL8
46 cytomegalovirus infection 30.6 TNF IL6 IL1B CXCL8
47 constipation 30.6 TNF PTGS2 IL6 GAST
48 gastric adenocarcinoma 30.6 TP53 TNF PTGS2 IL6 IL1B GAST
49 bronchopneumonia 30.5 TNF IL6 IL1B CXCL8
50 cholangiocarcinoma 30.5 TP53 PTGS2 IL6 EGFR

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 109)

Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Maxillary Sinusitis
Chronic Pulmonary Heart Disease Chronic Rhinitis
Chylomicron Retention Disease Conn's Syndrome
Conversion Disorder Cystitis
Deficiency Anemia Dependent Personality Disorder
Dermatomycosis Diabetic Polyneuropathy
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix First-Degree Atrioventricular Block
Gallbladder Disease Gastrin Secretion Abnormality
Gastritis, Familial Giant Hypertrophic Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatitis
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome

Graphical network of the top 20 diseases related to Esophagitis:

Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:

pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 CTHRC1 EGFR GAST HRH2 IL13 IL1B
2 growth/size/body region MP:0005378 10.34 ASCC1 EGFR IL13 IL1B IL33 IL4
3 digestive/alimentary MP:0005381 10.33 EGFR GAST HRH2 IL13 IL33 IL4
4 hematopoietic system MP:0005397 10.32 CCL11 EGFR IL13 IL1B IL33 IL4
5 immune system MP:0005387 10.32 CCL11 EGFR GAST IL13 IL1B IL33
6 endocrine/exocrine gland MP:0005379 10.24 EGFR GAST HRH2 IL13 IL33 IL4
7 integument MP:0010771 10.2 EGFR IL13 IL1B IL33 IL4 IL6
8 adipose tissue MP:0005375 10.1 EGFR IL33 IL6 PTGS2 SOD2 TNF
9 nervous system MP:0003631 10.1 CTHRC1 EGFR HRH2 IL13 IL1B IL33
10 liver/biliary system MP:0005370 10.09 CTHRC1 EGFR IL4 IL5 IL6 PTGS2
11 neoplasm MP:0002006 10.02 EGFR GAST IL1B IL5 IL6 PTGS2
12 muscle MP:0005369 10.01 CTHRC1 EGFR IL13 IL6 PTGS2 SOD2
13 reproductive system MP:0005389 9.85 EGFR IL13 IL33 IL4 IL5 IL6
14 no phenotypic analysis MP:0003012 9.8 EGFR IL13 IL33 IL4 PTGS2 TNF
15 respiratory system MP:0005388 9.7 CCL11 EGFR IL13 IL33 IL4 IL5
16 skeleton MP:0005390 9.32 CTHRC1 EGFR IL13 IL1B IL33 IL4

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Famotidine Approved Phase 4 76824-35-6 3325
Trimebutine Approved Phase 4 39133-31-8
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Ondansetron Approved Phase 4 99614-02-5 4595
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Pemetrexed Approved, Investigational Phase 4 137281-23-3, 150399-23-8 60843 446556
leucovorin Approved Phase 4 58-05-9 6006 143
Calcium polycarbophil Approved Phase 4 126040-58-2
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Citalopram Approved Phase 4 59729-33-8 2771
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
Ramosetron Investigational Phase 4 132036-88-5
Rebamipide Investigational Phase 4 90098-04-7
22 Mosapride Investigational Phase 4 112885-41-3
Polaprezinc Experimental Phase 4 107667-60-7
24 Indobufen Investigational Phase 4 63610-08-2
25 Parasympatholytics Phase 4
26 Psychotropic Drugs Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 Anti-Anxiety Agents Phase 4
29 Emetics Phase 4
30 Antipsychotic Agents Phase 4
31 glucocorticoids Phase 4
32 Soy Bean Phase 4
33 Cromolyn Sodium Phase 4
34 Serotonin Receptor Agonists Phase 4
35 Olive Phase 4
36 Vitamin B Complex Phase 4
37 Folic Acid Antagonists Phase 4
38 Folate Phase 4
39 N-Methylaspartate Phase 4
40 Vitamin B9 Phase 4
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
42 Laxatives Phase 4
43 Cathartics Phase 4
44 Psyllium Phase 4
45 Acidophilus Phase 4
46 Anti-Allergic Agents Phase 4
47 Dermatologic Agents Phase 4
48 Bronchodilator Agents Phase 4
49 Neurotransmitter Agents Phase 4
50 Pharmaceutical Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 681)
# Name Status NCT ID Phase Drugs
1 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
6 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
7 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
8 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
9 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis. Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
10 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
11 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
12 The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis Completed NCT01874535 Phase 4 Esomeprazole 40 mg
13 A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
14 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
15 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
16 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed. Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
17 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
18 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
19 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
20 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
21 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
22 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
23 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment Completed NCT00242736 Phase 4 Esomeprazole
24 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
25 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
26 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
27 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
28 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
29 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
31 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
34 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
35 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
36 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
37 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00574925 Phase 4 Esomeprazole
38 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
39 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
40 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
41 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
42 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
43 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
44 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
45 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
46 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
47 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
48 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
49 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
50 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Pantoprazole sodium

Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

Lung, Testes, Bone, Liver, Smooth Muscle, Colon, Heart

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 12966)
# Title Authors PMID Year
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. 61 54
20208004 2010
Regulation of CDX2 expression in esophageal adenocarcinoma. 54 61
19415720 2009
Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. 61 54
18844613 2008
[Eosinophilic esophagitis : a cause of dysphagia]. 54 61
18214405 2008
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. 54 61
18073124 2007
Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. 61 54
17900656 2007
Alterations in manganese superoxide dismutase expression in the progression from reflux esophagitis to esophageal adenocarcinoma. 61 54
17473952 2007
Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. 54 61
17059896 2006
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 54 61
16868800 2006
Roles of epidermal growth factor and Na+/H+ exchanger-1 in esophageal epithelial defense against acid-induced injury. 61 54
16306134 2006
What is the best way to manage GERD symptoms in the elderly? 54 61
16510061 2006
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. 54 61
16453027 2006
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 54 61
16302983 2005
Eosinophilic esophagitis. 61 54
16282772 2005
Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. 54 61
15884106 2005
The relationship between the esophageal tissue content of neurotensin and the presence or absence of esophageal inflammation. 54 61
14992433 2004
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. 54 61
14724818 2003
Regulation of Na/H exchanger-1 in gastroesophageal reflux disease: possible interaction of histamine receptor. 54 61
14561010 2003
Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. 61 54
12560917 2003
Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis. 61 54
12392390 2002
Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. 54 61
11474496 2001
The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. 54 61
11403754 2001
Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. 61 54
11121210 2001
Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture. 61 54
10900424 2000
Gastroesophageal reflux disease: pathophysiology and pharmacology overview. 54 61
10826019 2000
Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. 61 54
10492161 1999
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance. 61 54
9165690 1996
Novel Findings on SPECT-CT Tc-99 Sestamibi Imaging for Primary Hyperparathyroidism. 61
32289578 2020
Is coffee ground vomiting important? Findings from a large bleeding unit database and outcomes at 30 days. 61
32175981 2020
Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status. 61
32454972 2020
Long-Term Evaluation of Biliary Reflux on Esogastric Mucosae after One-Anastomosis Gastric Bypass and Esojejunostomy in Rats. 61
32130650 2020
Post-POEM reflux: who's at risk? 61
31628620 2020
Gastric myotomy length affects severity but not rate of post-procedure reflux: 3-year follow-up of a prospective randomized controlled trial of double-scope per-oral endoscopic myotomy (POEM) for esophageal achalasia. 61
31463720 2020
Erosive Esophagitis and Symptoms of Gastroesophageal Reflux Disease in Patients with Morbid Obesity with and without Type 2 Diabetes: a Cross-sectional Study. 61
32193740 2020
Approaches to diet therapy for eosinophilic esophagitis. 61
32398563 2020
Impedance and Histologic Characteristics of the Sub-Laryngeal Esophagus Distinguish Eosinophilic Esophagitis From Other Esophageal Disorders. 61
31589979 2020
Differences in Management of Eosinophilic Esophagitis in Europe: An Assessment of Current Practice. 61
32097371 2020
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer. 61
32439358 2020
Impact of early gastroesophageal reflux disease on childhood otologic outcomes. 61
32371356 2020
Dabigatran-induced esophagitis masking esophageal cancer. 61
32505570 2020
Endoscopic Findings 5 Years Following Sleeve Gastrectomy. 61
32524524 2020
Recurrent Candidal Esophagitis and Esophageal Carcinoma in a Kidney Transplant Recipient. 61
32539549 2020
Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy. 61
32512833 2020
The yield, effectiveness and safety of gastroscopy in management of early postbariatric upper gastrointestinal pain. 61
32550725 2020
How Does Vonoprazan Affect the Treatment of Erosive Esophagitis? 61
32535777 2020
Doxycycline-induced spongiotic esophagitis is associated with eosinophilic vascular degeneration. 61
32533730 2020
Ulcerative esophagitis associated with combined nivolumab and ipilimumab therapy. 61
32490540 2020
Pill-induced esophagitis caused by ingesting excessive caffeine tablets. 61
31646430 2020
Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India. 61
32514456 2020
Yunnan Baiyao diminishes lipopolysaccharide-induced inflammation in osteoclasts. 61
32189353 2020

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
Show member pathways
14.1 TP53 TNF PTGS2 IL6 IL5 IL4
Show member pathways
13.89 TP53 TNF PTGS2 IL6 IL5 IL4
Show member pathways
Show member pathways
13.61 TP53 TNF IL6 IL5 IL4 IL1B
Show member pathways
13.45 TP53 TNF IL6 IL5 IL4 IL1B
Show member pathways
13.41 TP53 TNF PTGS2 IL6 IL5 IL4
Show member pathways
13.38 TNF IL6 IL5 IL4 IL1B IL13
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.94 TNF IL6 IL5 IL4 IL1B IL13
12 12.93 TP53 PTGS2 IL6 IL5 IL4 IL13
Show member pathways
12.9 TP53 TNF IL6 IL33 IL1B CXCL8
Show member pathways
Show member pathways
Show member pathways
12.69 TNF IL6 IL5 IL4 IL1B IL13
Show member pathways
12.66 TP53 TNF IL6 IL1B EGFR
Show member pathways
12.66 TNF PTGS2 IL5 IL4 IL13
Show member pathways
12.56 TSLP IL6 IL5 IL4 IL13 EGFR
Show member pathways
12.53 TP53 IL5 IL1B IL13 EGFR
21 12.48 TP53 TNF IL1B EGFR CXCL8
Show member pathways
12.43 TNF IL6 CXCL8 CCL26 CCL11
Show member pathways
Show member pathways
12.42 TP53 TNF SOD2 PTGS2 IL6 IL4
25 12.36 TNF IL6 IL1B CXCL8
Show member pathways
12.36 TP53 TNF IL6 IL5 IL4 IL1B
Show member pathways
12.36 TNF PTGS2 IL6 IL5 IL4 IL1B
28 12.33 TNF IL6 IL1B CXCL8
Show member pathways
12.32 TNF PTGS2 IL4 IL1B
30 12.3 TNF IL6 IL1B CXCL8
31 12.29 TP53 TNF PTGS2 IL6 EGFR
Show member pathways
12.29 TNF IL6 IL4 IL1B CXCL8 CCL11
Show member pathways
12.28 TNF PTGS2 IL6 IL1B
34 12.28 TNF IL6 IL1B IL13 CXCL8
Show member pathways
12.14 TP53 IL5 IL1B IL13 EGFR
36 12.1 TNF IL6 IL1B CXCL8
37 12.08 TNF IL6 IL5 IL4
38 12.06 TNF PTGS2 IL6 IL1B
39 12.04 TP53 IL6 IL1B CXCL8
40 12.03 TNF PTGS2 IL1B CXCL8
41 12.02 TNF IL6 IL5 IL4 IL1B
42 12.01 TNF IL6 IL1B CXCL8
43 12 TNF IL6 IL1B CXCL8
44 12 TP53 TNF PTGS2 IL6 IL4 IL1B
45 11.96 TNF IL6 IL1B CXCL8
46 11.93 TP53 IL6 IL5 IL4 IL13 CXCL8
Show member pathways
48 11.88 TSLP TNF IL5 IL4 IL33 IL1B
49 11.87 TNF IL6 IL1B CXCL8
50 11.8 TNF IL6 IL1B

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TSLP TNF IL6 IL5 IL4 IL33
2 extracellular space GO:0005615 9.47 TSLP TNF IL6 IL5 IL4 IL33

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 TSLP IL6 IL5 IL4 IL1B HRH2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TP53 TNF IL6 IL4 IL33 IL1B
3 positive regulation of transcription, DNA-templated GO:0045893 10.14 TP53 TNF IL6 IL5 IL4 IL1B
4 negative regulation of apoptotic process GO:0043066 10.13 TSLP TP53 PTGS2 IL6 IL4 EGFR
5 positive regulation of cell proliferation GO:0008284 10.11 TSLP PTGS2 IL6 IL5 IL4 IL1B
6 negative regulation of cell proliferation GO:0008285 10.1 TP53 SOD2 PTGS2 IL6 IL1B CXCL8
7 positive regulation of gene expression GO:0010628 10.07 TP53 TNF IL6 IL4 IL33 IL1B
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TNF EGFR CCL26 CCL11
9 regulation of cell proliferation GO:0042127 10.01 TP53 TNF PTGS2 EGFR
10 cellular response to lipopolysaccharide GO:0071222 9.99 TNF IL6 IL1B CXCL8
11 positive regulation of cell migration GO:0030335 9.97 SOD2 IL4 IL1B EGFR CCL26 CCL11
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL5 IL1B
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 TNF PTGS2 IL6 EGFR
14 cellular response to mechanical stimulus GO:0071260 9.91 PTGS2 IL1B IL13 EGFR
15 neutrophil chemotaxis GO:0030593 9.9 IL1B CXCL8 CCL26 CCL11
16 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CCL26 CCL11
17 cellular response to drug GO:0035690 9.88 TP53 IL1B EGFR
18 response to glucocorticoid GO:0051384 9.88 TNF PTGS2 IL6
19 positive regulation of inflammatory response GO:0050729 9.88 TSLP TNF IL33 IL1B EGFR
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF IL1B EGFR
21 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL4 IL1B
22 monocyte chemotaxis GO:0002548 9.85 IL6 CCL26 CCL11
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF PTGS2 IL1B
24 positive regulation of B cell proliferation GO:0030890 9.85 IL5 IL4 IL13
25 negative regulation of mitotic cell cycle GO:0045930 9.84 TP53 TNF EGFR
26 positive regulation of vasoconstriction GO:0045907 9.83 PTGS2 HRH2 EGFR
27 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL5
28 microglial cell activation GO:0001774 9.81 TNF IL4 IL13
29 positive regulation of vascular endothelial growth factor production GO:0010575 9.81 PTGS2 IL6 IL1B
30 inflammatory response GO:0006954 9.81 TNF PTGS2 IL6 IL5 IL1B IL13
31 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TSLP TNF IL6 IL4 IL13
32 positive regulation of chemokine production GO:0032722 9.79 TSLP TNF IL6
33 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
34 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF PTGS2 IL6 IL13 EGFR
35 astrocyte activation GO:0048143 9.76 TNF IL1B EGFR
36 positive regulation of chemokine biosynthetic process GO:0045080 9.75 TNF IL4 IL1B
37 positive regulation of interleukin-10 secretion GO:2001181 9.73 IL4 IL13
38 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL6 IL5 IL33
39 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B CCL11
40 regulation of neuroinflammatory response GO:0150077 9.72 PTGS2 IL6
41 positive regulation of mast cell degranulation GO:0043306 9.72 IL4 IL13
42 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.72 TP53 TNF
43 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
44 response to salt stress GO:0009651 9.72 TP53 TNF
45 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.72 TP53 IL6 EGFR
46 positive regulation of interleukin-6 production GO:0032755 9.72 TSLP TNF IL6 IL33 IL1B
47 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
48 positive regulation of interleukin-5 production GO:0032754 9.7 TSLP IL33
49 positive regulation of mononuclear cell migration GO:0071677 9.69 TNF IL4
50 positive regulation of interleukin-13 production GO:0032736 9.69 TSLP IL4 IL33

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TSLP TNF IL6 IL5 IL4 IL33
2 chemokine activity GO:0008009 9.33 CXCL8 CCL26 CCL11
3 CCR3 chemokine receptor binding GO:0031728 8.96 CCL26 CCL11

Sources for Esophagitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....